McKinsey, Opiods, and The Dark Side of High Performance

Earlier this week, the New York Times broke a story detailing how the prestigious consulting firm McKinsey and Company “proposed paying pharmacy companies rebates for Oxycontin [a popular opioid] overdoses.” Worse, partners at McKinsey allegedly tried to cover the evidence of their recommendation. In this episode of The Growth Equation podcast, Brad, a former McKinsey consultant himself, and Steve use this moral failure as a jumping off point to discuss ethical creep in high-performance organizations and cultures—from the corporate world, to start-ups, to sports—and what we can do to prevent it in ourselves and those we coach, parent, teach, and lead.Please write a review on Apple Podcasts and help new listeners discover the show!You can find the podcast on:iTunes and Apple PodcastsSpotifyAndroidStitcherFind Brad and Steve on Twitter: @Bstulberg and @stevemagness(NYT Story on Opiods: https://www.nytimes.com/2020/11/27/business/mckinsey-purdue-oxycontin-opioids.html)The post McKinsey, Opiods, and The Dark Side of High Performance appeared first on The Growth Equation. Hosted on Acast. See acast.com/privacy for more information.

There are no comments yet.

Please log in to write the first comment.